Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
In Manila, pharmacy valuation is 80-110 % of revenue (90 % average), with a regulated gross margin of 26-32 %. New creation is extremely rare (transfer/merger only).
Dominant profile: business · capitale
Manila (Metro Manila, Philippines) has about 1.8M inhabitants and shows dense business fabric (HQs, B2B services, professionals), and capital-city status (administration, embassies, official events) smoothing off-season demand. For a pharmacy project, this means a constrained average ticket and a setup cost below national by 50 %.
The market can still absorb a well-positioned entrant, provided a clear niche is targeted. Concretely, initial investment calibrated for Manila ranges from 400K PHP to 1.8M PHP, and Year 1 target revenue sits between 600K PHP and 1.8M PHP — a range that already factors in the local coefficients of this city (−50% vs average on costs, −60% vs average on purchasing power).
Competitive density: medium (clear niches still open).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 600K PHP → 1.8M PHP | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Manila, Philippines (cost −50% vs average, income −60% vs average).
This page combines multiple data sources for a factual analysis calibrated on Manila.
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.